Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 38 entries
View as:

Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection

Phase: N/A Priority: Normal
NCT ID: NCT06982547 Org: User:
Start: 06/30/25 End: 06/30/40 Due: 06/30/41

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Phase: N/A Priority: Normal
NCT ID: NCT02944162 Org: User:
Start: 10/31/16 End: 09/30/18 Due: 09/30/19

Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

Phase: N/A Priority: Normal
NCT ID: NCT06982534 Org: User:
Start: 06/30/25 End: 01/31/40 Due: 01/31/41

Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor

Phase: N/A Priority: Normal
NCT ID: NCT04650724 Org: User:
Start: 10/11/18 End: 10/01/20 Due: 10/01/21

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02742727 Org: User:
Start: 03/31/16 End: 03/31/18 Due: 03/31/19

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06361745 Org: User:
Start: 04/02/24 End: 03/01/25 Due: 03/01/26

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04785833 Org: User:
Start: 03/04/21 End: 02/04/24 Due: 02/04/25

CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04237428 Org: User:
Start: 05/31/19 End: 05/31/21 Due: 05/31/22

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT05562024 Org: User:
Start: 12/30/22 End: 02/18/39 Due: 02/18/40

Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04186052 Org: User:
Start: 03/08/19 End: 03/01/21 Due: 03/01/22

TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05017883 Org: User:
Start: 07/01/21 End: 10/31/25 Due: 10/31/26

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05731219 Org: User:
Start: 09/26/22 End: 09/26/25 Due: 09/26/26

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03999697 Org: User:
Start: 12/01/18 End: 12/01/20 Due: 12/01/21

CAR-T for r/r Malignant Tumors in Children

Phase: N/A Priority: Normal
NCT ID: NCT04691349 Org: User:
Start: 09/27/20 End: 09/26/21 Due: 09/26/22

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06417398 Org: User:
Start: 05/14/24 End: 05/01/25 Due: 05/01/26

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02819583 Org: User:
Start: 10/31/16 End: 09/30/19 Due: 09/30/20

Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06970951 Org: User:
Start: 05/18/25 End: 04/30/27 Due: 04/30/28

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04691713 Org: User:
Start: 09/01/19 End: 12/01/21 Due: 12/01/22

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT04864821 Org: User:
Start: 05/14/21 End: 05/14/23 Due: 05/14/24

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06279026 Org: User:
Start: 04/01/24 End: 07/01/27 Due: 07/01/28

γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse

Phase: N/A Priority: Normal
NCT ID: NCT04439721 Org: User:
Start: 05/01/20 End: 05/01/21 Due: 05/01/22

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

Phase: N/A Priority: Normal
NCT ID: NCT04480788 Org: User:
Start: 11/24/20 End: 08/31/22 Due: 08/31/23

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT02617134 Org: User:
Start: 11/30/15 End: 11/30/18 Due: 11/30/19

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT02587689 Org: User:
Start: 10/31/15 End: 10/31/18 Due: 10/31/19

Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05722171 Org: User:
Start: 12/27/22 End: 12/27/24 Due: 12/27/25